

1 Title page:

2 Pilot study assessing the use of cabergoline for the treatment of cats with

3 hypersomatotropism and diabetes mellitus

4 Christopher J Scudder<sup>1,2</sup>

5 Katarina Hazuchova<sup>3</sup>

6 Ruth Gostelow<sup>3</sup>

7 David B Church<sup>3</sup>

8 Yaiza Forcada<sup>3,4</sup>

9 Robert C Fowkes<sup>1</sup>

10 Stijn JM Niessen<sup>3,4,5</sup>

11 1. Comparative Biomedical Sciences, The Royal Veterinary College, AL97TA Hatfield, UK

12 2. Small Animal Internal Medicine Department, Southfields Veterinary Specialists, SS15

13 6TP, Basildon, UK

14 3. Clinical Science and Services, The Royal Veterinary College, AL97TA Hatfield, UK

15 4. VetCT Telemedicine Hospital, CB4 0WS, Cambridge UK

16 5. Diabetes Research Group, Institute of Cellular Medicine, University of Newcastle, NE2

17 4HH, Newcastle, UK

18 Corresponding author: Christopher Scudder BVSc, MVetMed, Ph.D, DACVIM-SAIM,

19 DECVIM-CA, MRCVS. Tel: +441268 564664, Comparative Biomedical Sciences, The Royal

- 20 Veterinary College, AL97TA Hatfield, UK and Small Animal Internal Medicine
- 21 Department, Southfields Veterinary Specialists, SS15 6TP, Basildon, UK
- 22 Keywords: acromegaly, pituitary, growth-hormone, IGF1

## 23 Abstract

24 Objectives: An affordable and effective treatment is needed to manage feline  
 25 hypersomatotropism ~~/acromegaly~~. The study aim was to assess whether treatment with  
 26 oral cabergoline for 90 days in cats with hypersomatotropism and diabetes mellitus  
 27 improves diabetic and insulin-like growth factor 1 control.

28 Methods: Prospective cohort non-blinded pilot study enrolling client owned cats with  
 29 spontaneously occurring diabetes mellitus and hypersomatotropism. Cats received oral  
 30 cabergoline (5 to 10 µg/kg q24 h) for 90 consecutive days. Serum insulin-like growth  
 31 factor 1 and fructosamine concentrations were measured on days 1, 5, 30 and 90.

32 Quality of life was determined using the DIAQoL-pet questionnaire on days 1 and 90.

33 Results: Nine cats were enrolled and eight completed the study. There was no  
 34 significant change of insulin-like growth factor 1 (day 1 median was 2001 [range 890 to  
 35 2001]; day 30 median was 2001 [range 929 to 2001]; day 90 median was 1828 [range  
 36 1035 to 2001] ng/mL ( $X^2(2) = 0.667$ ,  $P = 0.805$ ), fructosamine (day 1 median was 499  
 37 [range 330 to 887], day 30 median was 551 [range 288 to 722], day 90 median was 503  
 38 [range 315 to 851] µmol/L,  $X^2(2) = 0.581$ ,  $P = 0.764$ ), or DIAQoL-pet score (median on  
 39 day 1 was -2.79 [range -4.62 to -0.28], median on day 90 was -3.24 [range -4.41 to -  
 40 0.28],  $P = 0.715$ ). There was a significant change of insulin dose ( $X^2(2) = 8.667$ ,  $P = 0.008$ )  
 41 with cats receiving higher insulin doses at day 90 compared to day 1 (median day 1 was

42 0.98 [range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg q12h,

43  $P = 0.026$ .

44 Conclusions and relevance: Cabergoline did not improve diabetic or normalise insulin-

45 like growth factor concentration, nor improve patient quality of life.

46

47 Introduction:

48 Hypersomatotropism (HST) in cats is a condition caused by chronic excessive  
49 growth hormone (GH). Most cats with HST have concurrent diabetes mellitus (DM)  
50 which can be difficult to control using treatments which only target glycemic  
51 control.

52

53 Medical management using pasireotide or surgical management via  
54 hypophysectomy has improved GH and diabetic control in cats with HST.<sup>1-3</sup>  
55 However, these treatments are often too costly for owners and effective alternative  
56 modalities are needed.

57

58 In human medicine, HST is known as acromegaly due to the phenotypic changes  
59 induced by the condition. There are three main medical management options for  
60 acromegaly in humans which are somatostatin receptor agonists (SRAs) such as  
61 octreotide or pasireotide, dopamine receptor agonists (DRAs) such as  
62 bromocriptine or cabergoline and growth hormone receptor antagonists, namely

pegvisomant. Recommendations suggest the primary medical treatment of patients who have moderate-to-severe disease should be SRAs and patients who have mild disease (serum insulin-like growth factor 1 [IGF1] < 2 times the upper limit of the age adjusted range) can be treated using a DRA.<sup>4,5</sup> The direct mechanism of action of GH-secretion inhibition by DRAs is thought to be via somatotrope dopamine 2 receptors (D2Rs) within the pituitary.<sup>6</sup> As cats with HST have pituitary expression of D2R, therapy with a DRA might result in improved GH control and therefore diabetic control.<sup>7</sup>

Cabergoline and bromocriptine are DRAs with high affinity for D2R in rats and monkeys<sup>8,9</sup>. Cabergoline is the D2R-specific DRA with more favourable properties, having a longer action of duration and thus requires less frequent dosing, is better tolerated and exhibits increased insulin sensitising effects independent of GH reduction compared to bromocriptine.<sup>10,11</sup> An oral preparation of cabergoline was licensed and available for use in cats at the time of study (Kelactin, Kela N.V.) Cabergoline has also been proven to be well tolerated when administered for

several months in both dogs and humans.<sup>12,13</sup>

The aim of the pilot study was to determine if cats with HST and DM experienced decreased serum IGF1 and improved diabetic control determined by serum fructosamine concentration and insulin dose requirement when receiving once daily treatment with oral cabergoline. A secondary aim of the study was to determine whether this treatment resulted in improved quality of life of these cats.

## Materials and methods

The study was approved by the Ethics and Welfare Committee of the Royal Veterinary College, UK; URN 2016 1604. Informed written consent was obtained from all owners before enrolment. Cats with HST were prospectively enrolled between 01/10/2016 and 31/05/2017. Inclusion criteria were DM which had been treated for at least four weeks prior to enrolment, serum IGF1 concentration >700 ng/mL with pituitary enlargement (>4mm dorsoventral height) or serum IGF1 >1000 ng/mL without pituitary imaging. Since IGF1 >1000 ng/mL has been shown

to have a positive predictive value for HST of 95% in the UK diabetic cat population where the prevalence of HST was 25%, necessity of additional pituitary imaging in this group was not deemed essential.<sup>14</sup> If contrast enhanced pituitary imaging had not already been performed and the owner consented to the procedure, then this was undertaken on day 1 as previously described.<sup>15</sup> Exclusion criteria were poor patient tolerance of veterinary procedures, uncontrolled hyperthyroidism, insulin antagonist therapy within the preceding four weeks prior to enrolment or if they had a disease which was more critical to the cat's welfare than HST as judged by the attending clinician.

Owners of eligible cats were offered a reduced fee for contrast enhanced CT of their cat, free supply of PZI insulin (Prozinc, Boehringer Ingelheim) and diabetic cat food (Purina DM, Nestle Purina) for the length of the study. Owners paid for the initial period of hospitalization and the cost of cabergoline during the study. Owners were encouraged to perform home blood glucose monitoring.



On day 1, a blood sample was collected for pre-treatment CBC, serum biochemistry, serum IGF1 and fructosamine concentration determination. Cats had a subcutaneous interstitial glucose monitor (Guardian REAL Time Continuous Glucose Monitoring System, Medtronic) placed to measure glycemic control for an initial period of hospitalization of four days<sup>17</sup>. Cats received the same insulin dose and frequency as prescribed by their referring veterinarian prior to enrolment on day 1, cats were prescribed oral cabergoline once daily starting on day 2 and were discharged on day 5. Cats were monitored for possible adverse drug effects, whether there was increased sensitivity to insulin therapy as determined by glycemic control during hospitalization, clinical sign monitoring by their owners and repeat fructosamine measurement on days 30 and 90, and IGF1 measurements were repeated on days 30 and 90 (Figure 1).

Patient quality of life (QoL) was assessed by requesting owners to complete the psychometric DIAQoL-pet questionnaire at day 1 and 90. The DIAQoL-pet has previously been validated to quantify owner perceived QoL of diabetic pet and

owner, and can quantify the effect of treatment upon their diabetic cat's quality of life as well as their own.<sup>18</sup>

#### Statistical Analysis

A P value < 0.05 was considered significant. Data were analysed for normal distribution visually using histograms and by performing Shapiro–Wilk tests. Any IGF1 concentration > 2000 ng/mL was analysed as being 2001 ng/mL. Non-normally distributed data are presented as median and range and data with normally distributed data presented as mean and standard deviation (S.D.). Friedman tests and post-hoc related samples Wilcoxon signed rank tests with Bonferroni adjustment where appropriate were performed to compare repeated measures IGF1, fructosamine and insulin dose data on days 1, 30 and 90. Related samples Wilcoxon signed rank test was used to compare QoL data on days 1 and 90. The Spearman rank test was used to compare the strength of correlation between data. Statistical analyses were performed using statistical software

(GraphPad Prism version 8.4.0 for macOS, GraphPad Software and IBM SPSS Statistics Version 26.0.0.0 for macOS, IBM Corp).

## Results

Nine cats were enrolled, eight cats completed the study and one cat (cat 1) died during the study. The data from the cat which did not complete the study was excluded from these analyses of insulin dose, fructosamine, IGF1 and DIAQol-pet scores. All nine cats were DSH breed, six were male and three were female, the mean age was 10.8 years (S.D. 2.8), mean weight was 4.8 kg (S.D. 0.8), mean pituitary dorsoventral height was 6.3 mm (S.D. 1.6) and median pituitary volume was 0.088 cm<sup>3</sup> (range 0.048 to 0.327). Cat 6 did not undergo intracranial CT imaging because of the concern this patient had a high risk for congestive heart failure as determined by echocardiographic measurements. Home blood glucose monitoring was performed by 4/9 owners. All owners reported they were successful when giving cabergoline to their cats and that the medication had been handled per manufacturer's instructions.

158

159 The first three cats enrolled on the study received 5 µg/kg cabergoline q24h but  
160 had a dose increase to 10 µg/kg q24h at day 30 to 35, and the remaining cats had  
161 a cabergoline dose of 10 µg/kg q24h from enrolment. Cat 7 did not have IGF1 and  
162 fructosamine measurements at day 30.

163

#### 164 Serum IGF1 results

165 There was no significant change of serum IGF1 concentration over the three  
166 months of the study (day 1 median was 2001 [range 890 to 2001]; day 30 median  
167 was 2001 [range 929 to 2001]; day 90 median was 1828 [range 1035 to 2001]  
168 ng/mL,  $X^2(2) = 0.667$ ,  $P = 0.805$ ) (Figure 1). Four experienced a decrease and four  
169 an increase IGF1 from day 1 to day 90. The median pituitary volume of cats which  
170 experienced IGF1 reduction was not significantly different to those who did not  
171 experience a reduction of IGF1 (0.086 vs and 0.133 cm<sup>3</sup>,  $P = 0.94$ ).

172

#### 173 Serum fructosamine and insulin dose

174 There was no statistical difference of fructosamine concentration at any time point  
 175 (day 1 median was 499 [range 330 to 887], day 30 median was 551 [range 288 to  
 176 722], day 90 median was 503 [range 315 to 851],  $X^2(2) = 0.581$ ,  $P = 0.764$ ) (Figure  
 177 2). An insulin dose increase was prescribed for 6/8 cats. There was a significant  
 178 change of insulin dose prescribed during the study ( $X^2(2) = 8.667$ ,  $P = 0.008$ ), with  
 179 cats receiving higher insulin doses on day 90 compared to day 1 (median day 1 was  
 180 0.98 [range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg  
 181 q12h,  $P = 0.026$ .) (Figure 3).

182

### 183 DIAQol-pet scores

184 The DIAQol-pet was completed by 6/8 owners of cats. There was no statistical  
 185 change of DIAQoL-pet scores between day 1 and day 90 (median on day 1 was -  
 186 2.79 [range -4.62 to -0.28], median on day 90 was -3.24 [range -4.41 to -0.28],  $P =$   
 187 0.715), (Figure 4). DIAQoL-pet scores negatively correlated with insulin dose on day  
 188 1 but not on day 90 (Spearman's rank -0.871,  $P = 0.034$  and -0.257,  $P = 0.623$ ,  
 189 respectively).

190

191 Potential adverse drug effects

192 One cat died during the study period (cat 1 in Supplemental Table 1). General  
193 physical examination at enrolment of this cat was unremarkable apart from a grade  
194 2/6 systolic cardiac murmur. An echocardiogram was not performed at enrolment.  
195 On day 82, the cat developed tachypnoea and was diagnosed with supraventricular  
196 tachycardia and congestive heart failure. The cat's owners elected for him to be  
197 euthanized and a post-mortem examination was declined.

198

199 Cat 7 did not have fructosamine or IGF1 data for day 30 because he was  
200 hospitalized at his local veterinary practice for an episode of presumed pancreatitis  
201 on day 28. Cat 5 experiencing reduced appetite and small intestinal diarrhea which  
202 resolved within one week without specific treatment, and the same cat experienced  
203 asymptomatic hypoglycemia on day 60. Two other cats experienced self-limiting  
204 inappetence of unknown cause lasting less than one week. No owner requested  
205 withdrawal from the study due to concern of possible adverse drug effects.

206

## 207 Discussion

208 This is the largest case series to-date to describe cats with HST and DM treated  
209 with cabergoline. Although a direct measurement of insulin sensitivity was not  
210 performed, the trend for increasing requirement for exogenous insulin with similar  
211 serum fructosamine concentrations infers the cats experienced increasing insulin  
212 resistance. This is likely due to ongoing uncontrolled HST because cabergoline did  
213 not reliably control IGF1 concentration by decreasing it to within the reference  
214 interval.

215

216 There are no published studies describing the pharmacokinetics of cabergoline in  
217 cats. The plasma elimination half-life is between 63 to 109 hours in humans.<sup>8</sup> The  
218 initial dose of 5 µg/kg q24h by mouth was chosen because this was the licensed  
219 dose for the treatment of inappropriate lactation in cats, and this dose was  
220 effective in terminating pregnancy in queens which suggests effective suppression  
221 of prolactin secretion.<sup>19</sup> This dose is equivalent to 0.5 mg q24h dose for an average

222 human using mg/kg dosing, which is reported to result in GH suppression in  
223 humans with acromegaly.<sup>20</sup> However, other studies have reported using higher  
224 doses of cabergoline to treat cats and the medication was well tolerated, and some  
225 humans with acromegaly require higher doses to achieve biochemical response.<sup>21,22</sup>  
226 This was part of the rationale for increasing the initial cabergoline dose from 5 to  
227 10 µg/kg q24h for cats 4 to 9.

228

229 The findings of this study differ from the results of a case series of three cats with  
230 HST and DM treated with 10 µg/kg q48h cabergoline for three months.<sup>23</sup> All the  
231 cats in that study experienced decreased IGF1 and improved insulin sensitivity after  
232 treatment. It is possible that the cause of HST in cats was different to the cause of  
233 HST in this study as different pituitary adenoma subtypes are known to respond  
234 differently to medical management.<sup>24,25</sup> Response to cabergoline therapy can also  
235 vary depending on prior treatments, alternative splicing of DRD2 mRNA,  
236 magnitude of dopamine receptor expression at the protein level or defective  
237 signalling pathways downstream of DR2 stimulation.<sup>26–29</sup> It has been reported that



cats with hypersomatotropism have a moderate negative correlation between *DRD2* expression and pituitary size<sup>7</sup>. That data suggests that pituitary size might be related to cabergoline responsiveness, but there was no difference of pituitary size between those who experienced an IGF1 decrease versus those who did not in this study. The low number of patients enrolled on this study will be a limiting factor to identify the effect of pituitary size and cabergoline responsiveness. A study investigating the effect of DR2 protein expression and cabergoline responsiveness is indicated to better determine the variability of cabergoline effect between patients.

Cabergoline is typically recommended for the treatment of acromegaly in humans who have mild clinical signs and IGF1 concentrations less than 1.5 to 2 times above the reference interval.<sup>5,30</sup> There were 6/9 cats who had serum IGF1 concentrations > 2000 ng/mL at the start of the study and only two cats had IGF1 concentrations less than twice the laboratory reference interval. It is possible that the severity of HST in these cats was inappropriate for cabergoline treatment. Apart from decreasing

IGF1, cabergoline might exert antidiabetic effects by increasing insulin sensitivity without affecting GH levels.<sup>31</sup> This mechanism could explain the response of cat 5 who was receiving a lower dose of insulin and had lower serum fructosamine despite slightly increased IGF1 at day 90 compared to day 1.

Consideration and measurement of QoL is increasingly important when undertaking clinical studies and particularly important in veterinary medicine as a common reason for euthanasia of a cat with DM is owner perceived poor pet QoL.<sup>32–34</sup> Acromegaly is associated with reduced QoL in humans and improves but does not normalize with disease control.<sup>35–38</sup> Diabetes in cats is associated with owner perceived reduced QoL of their cat and improved DM control has been associated with improved QoL.<sup>18,39</sup> Quality of life scores did not improve during the study which could be explained due to poor biochemical control of either HST or DM.

269 Clinical signs that might have been compatible with drug-induced adverse effects  
270 include an episode of presumed acute pancreatitis in one cat, 2/9 cats experienced  
271 inappetence presumed not associated with pancreatitis and one cat, which had  
272 experienced inappetence, also experienced self-limiting small intestinal diarrhoea  
273 lasting less than one week. Gastrointestinal adverse effects of cabergoline have  
274 previously been reported in cats receiving 15 µg/kg q24h.<sup>21</sup> Nausea and vomiting  
275 and vertigo are the most commonly reported side effects in cabergoline treated  
276 humans with hyperprolactinaemia, affecting up to 1/3 of those treated.<sup>40</sup>  
277 Cabergoline does not appear to induce pancreatitis in humans, and it is possible  
278 the cat which experienced pancreatitis did so independent of cabergoline  
279 treatment. ~~Pancreatic pathology in cats with DM appears to be common. One study~~  
280 ~~reported 83 % of diabetic cats having increased feline-specific pancreatic lipase~~  
281 ~~activity (fPLI), which is a marker of pancreatic inflammation.<sup>40</sup> Post-mortem~~  
282 ~~examinations of cats with DM describe up to half of patients having evidence of~~  
283 ~~chronic pancreatitis and 5 % having evidence of acute pancreatitis at the time of~~

284 death.<sup>44</sup> Additional studies are required to determine if cabergoline treatment is  
285 associated with pancreatitis in cats.

286  
287 In 2008, the Medicine and Healthcare products Regulatory Agency published a  
288 statement that cabergoline therapy might be associated with increased risk of  
289 cardiac fibrosis, and cardiac valvulopathy should be excluded prior to starting  
290 cabergoline therapy.<sup>41</sup> A recent systematic review concluded that the risk of  
291 cabergoline-associated valvulopathy in patients with prolactinoma is low, but the  
292 authors recommend an initial echocardiogram prior to starting cabergoline  
293 therapy.<sup>42</sup> Patient's affected by Parkinson's disease often receive cabergoline doses  
294 greater than 3 mg per day (around 40 µg/kg q24h for the average UK human)  
295 compared to 0.25 to 3 mg/week (equating to 3.125 to 39 µg/kg per week) in  
296 patients affected by prolactinoma and appear to have an increased risk of  
297 cabergoline induced cardiomyopathy.<sup>43–45</sup> The doses of cabergoline used in this  
298 study are more comparable with those used to treat prolactinoma than Parkinson's  
299 disease. Nonetheless, as 30 to 50 % of apparently healthy cats without a heart

murmur have echocardiographic evidence of heart disease, it is possible that the use of cabergoline might have contributed to progressive cardiac disease in patient 1 who died on day 82.<sup>46,47</sup> It is also possible this patient experienced progressive heart disease regardless of cabergoline therapy because HST in cats is associated with a hypertrophic cardiomyopathy phenotype and increased risk of congestive heart failure.<sup>48</sup> ~~As a result of the death of this patient, all subsequently enrolled patients underwent echocardiogram examination at enrolment and risk of progressive cardiac disease was discussed with owners. Owners were instructed to intermittently monitor their cat's resting respiratory rate at home because this is reported to be a sensitive indicator of congestive heart failure in cats.<sup>46</sup> Owners were instructed to contact the investigator if their cat's average resting respiratory rate was greater than 36 breaths per minute. No owner declined to enrol on the study after receiving this information and no further increased resting respiratory rate events occurred during the study period.~~

The low patient number will have affected the power of the study. However, this was a pilot study and as a previous report described a good response of three cats with diabetes and hypersomatotropism treated with cabergoline, this study provides evidence that not all cats experience a good response.<sup>23</sup> Another limitation is that IGF1 concentrations greater than 2000 ng/mL were not diluted to obtain the exact IGF1 concentration. The lack of exact IGF1 enumeration will have limited our ability to determine a difference during the study. ~~We wished to assess whether good control, as defined as IGF1 concentration within the reference interval, would be achieved.~~ Nonetheless, despite this limitation we can be confident reporting that no cat achieved normalization of serum IGF1.

## Conclusion

Although the study was underpowered, cabergoline does not appear to reliably control HST as the cats in this study did not achieve IGF1 control nor improved diabetic control.

332 Author note: Preliminary data from the study was presented as an oral research  
333 communication at 27th ECVIM CA Congress 2018.

334 Conflict of interest: none

335 Funding: The authors received no financial support for the research, authorship,  
336 and publication of this article. The Royal Veterinary College Diabetic Remission  
337 Clinic receives support from Boehringer Ingelheim, Nestlé Purina PetCare and  
338 Zoetis.

339 Ethical Approval: This work involved the use of non-experimental animals (owned  
340 or unowned) and procedures that differed from established internationally  
341 recognised high standards ('best practice') of veterinary clinical care for the  
342 individual patient. The study therefore had ethical approval from an established  
343 committee as stated in the manuscript.

344 Informed consent: Informed consent (either verbal or written) was obtained from  
345 the owner or legal custodian of all animals described in this work (nonexperimental  
346 animals) for the procedures undertaken (prospective studies). No animals or

347 humans are identifiable within this publication, and therefore additional informed  
348 consent for publication was not required.

349



## References:

1. Scudder CJ, Gostelow R, Forcada Y, et al. Pasireotide for the Medical Management of Feline Hypersomatotropism. *J Vet Intern Med* 2015; 29: 1074–1080.
2. Gostelow R, Scudder C, Keyte S, et al. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism. *J Vet Intern Med* 2017; 31: 355–364.
3. Meij BP, Auriemma E, Grinwis G, et al. Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. *J Feline Med Surg* 2010; 12: 406–410.
4. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2014; 99: 3933–3951.
5. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. *Nat Rev Endocrinol* 2014; 10: 243–248.
6. Beaulieu J-M, Gainetdinov RR. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. *Pharmacol Rev* 2011; 63: 182–217.
7. Scudder CJ, Mirczuk SM, Richardson KM, et al. Pituitary Pathology and Gene Expression in Acromegalic Cats. *J Endocr Soc* 2019; 3: 181–200.
8. Del Dotto P, Bonuccelli U. Clinical Pharmacokinetics of Cabergoline. *Clin Pharmacokinet* 2003; 42: 633–645.

- 370 9. Atsumi M, Kawakami J, Sugiyama E, et al. Pharmacokinetic and pharmacodynamic  
 371 analyses, based on dopamine D 2-receptor occupancy of bromocriptine, of  
 372 bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned  
 373 rats. *Synapse* 2003; 50: 110–116.
- 374 10. Dos Santos Nunes V, El Dib R, Boguszewski CL, et al. Cabergoline versus  
 375 bromocriptine in the treatment of hyperprolactinemia: A systematic review of  
 376 randomized controlled trials and meta-analysis. *Pituitary* 2011; 14: 259–265.
- 377 11. Krysiak R, Okopien B. Different Effects of Cabergoline and Bromocriptine on  
 378 Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin  
 379 Levels. *Basic Clin Pharmacol Toxicol* 2015; 116: 251–256.
- 380 12. Castillo VA, Gómez N V, Lalia JC, et al. Cushing's disease in dogs: Cabergoline  
 381 treatment. *Res Vet Sci* 2008; 85: 26–34.
- 382 13. Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the  
 383 long-term treatment of Cushing's disease. *Eur J Endocrinol* 2010; 163: 709–716.
- 384 14. Niessen SJM, Forcada Y, Mantis P, et al. Studying Cat (*Felis catus*) Diabetes: Beware  
 385 of the Acromegalic Imposter. *PLoS One* 2015; 10: e0127794.
- 386 15. Lamb CR, Ciasca TC, Mantis P, et al. Computed tomographic signs of acromegaly  
 387 in 68 diabetic cats with hypersomatotropism. *J Feline Med Surg* 2014; 16: 99–108.
- 388 16. Porciello F, Rishniw M, Ljungvall I, et al. Sleeping and resting respiratory rates in  
 389 dogs and cats with medically-controlled left-sided congestive heart failure. *Vet J*

- 2016; 207: 164–168.
17. Dietiker-Moretti S, Müller C, Sieber-Ruckstuhl N, et al. Comparison of a Continuous Glucose Monitoring System with a Portable Blood Glucose Meter to Determine Insulin Dose in Cats with Diabetes Mellitus. *J Vet Intern Med* 2011; 25: 1084–1088.
  18. Niessen SJM, Powney S, Guitian J, et al. Evaluation of a Quality-of-Life Tool for Cats with Diabetes Mellitus. *J Vet Intern Med* 2010; 24: 1098–1105.
  19. Kutzler MA. Estrus induction and synchronization in canids and felids. *Theriogenology* 2007; 68: 354–374.
  20. Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. *Clin Endocrinol* 1997; 46: 745–749.
  21. Erünal-Maral N, Aslan S, Findik M, et al. Induction of abortion in queens by administration of cabergoline (Galastop™) solely or in combination with the PGF2 $\alpha$  analogue Alfaprostol (Gabbrostim™). *Theriogenology* 2004; 61: 1471–1475.
  22. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. *J Clin Endocrinol Metab* 1998; 83: 374–378.
  23. Arias EAS, Garcia JD, Castillo VA. Pharmacological treatment with cabergoline in three cats with acromegaly. *Rev Colomb Cienc Pecu* 2017; 30: 316–321.
  24. Sarkar S, Chacko AG, Chacko G. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. *Acta*

- 410        *Neurochir (Wien)* 2014; 156: 2221–2230.
- 411    25.    Kiseljak-Vassiliades K, Carlson NE, Borges MT, et al. Growth hormone tumor  
412        histological subtypes predict response to surgical and medical therapy. *Endocrine*  
413        2015; 49: 231–241.
- 414    26.    Sandret L, Maison P, Chanson P. Place of Cabergoline in Acromegaly: A Meta-  
415        Analysis. *J Clin Endocrinol Metab* 2011; 96: 1327–1335.
- 416    27.    Shimazu S, Shimatsu A, Yamada S, et al. Resistance to dopamine agonists in  
417        prolactinoma is correlated with reduction of dopamine D2 receptor long isoform  
418        mRNA levels. *Eur J Endocrinol* 2012; 166: 383–390.
- 419    28.    Peverelli E, Treppiedi D, Giardino E, et al. Dopamine and somatostatin analogues  
420        resistance of pituitary tumors: Focus on cytoskeleton involvement. *Front*  
421        *Endocrinol (Lausanne)* 2015; 6: 1–10.
- 422    29.    Wu ZB, Zheng WM, Su ZP, et al. Expression of D2RmRNA isoforms and ERmRNA  
423        isoforms in prolactinomas: correlation with the response to bromocriptine and  
424        with tumor biological behavior. *J Neurooncol* 2010; 99: 25–32.
- 425    30.    Lee SY, Kim JH, Lee JH, et al. The efficacy of medical treatment in patients with  
426        acromegaly in clinical practice. *Endocr J* 2018; 65: 33–41.
- 427    31.    Bahar A, Kashi Z, Daneshpour E, et al. Effects of cabergoline on blood glucose  
428        levels in type 2 diabetic patients. *Medicine (Baltimore)* 2016; 95: e4818.
- 429    32.    Niessen S, Hazuchova K, Powney S, et al. The Big Pet Diabetes Survey: Perceived

- 430 Frequency and Triggers for Euthanasia. *Vet Sci* 2017; 4: 27.
- 431 33. Higginson IJ. Measuring quality of life: Using quality of life measures in the clinical  
432 setting. *BMJ* 2001; 322: 1297–1300.
- 433 34. Jacobsen PB, Davis K, Cella D. Assessing quality of life in research and clinical  
434 practice. *Oncology (Williston Park)* 2002; 16: 133–9.
- 435 35. Webb SM, Badia X, Surinach NL, et al. Validity and clinical applicability of the  
436 acromegaly quality of life questionnaire, AcroQoL: A 6-month prospective study.  
437 *Eur J Endocrinol* 2006; 155: 269–277.
- 438 36. Varewijck AJ, van der Lely AJ, Neggers SJCM, et al. In active acromegaly, IGF1  
439 bioactivity is related to soluble Klotho levels and quality of life. *Endocr Connect*  
440 2014; 3: 85–92.
- 441 37. Biermasz NR, Van Thiel SW, Pereira AM, et al. Decreased quality of life in patients  
442 with acromegaly despite long-term cure of growth hormone excess. *J Clin*  
443 *Endocrinol Metab* 2004; 89: 5369–5376.
- 444 38. Trepp R, Everts R, Stettler C, et al. Assessment of quality of life in patients with  
445 uncontrolled vs. controlled acromegaly using the acromegaly quality of life  
446 questionnaire (AcroQoL). *Clin Endocrinol (Oxf)* 2005; 63: 103–110.
- 447 39. Gostelow R, Hazuchova K, Scudder C, et al. Prospective evaluation of a protocol  
448 for transitioning porcine lente insulin-treated diabetic cats to human recombinant  
449 protamine zinc insulin. *J Feline Med Surg* 2018; 20: 114–121.

- 450 40. Colao A, Lombardi G, Annunziato L. Cabergoline. *Expert Opin Pharmacother* 2000;  
451 1: 555–574.
- 452 41. MRHA Drug Safety Update. *Monthly newsletter from the Medicines and*  
453 *Healthcare products Regulatory Agency and the Commission on Human*  
454 *Medicines* 2008; 2.
- 455 42. Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect  
456 cabergoline-associated valvulopathy in patients with prolactinoma: A systematic  
457 review and additional clinical data. *Lancet Diabetes Endocrinol* 2015; 3: 906–913.
- 458 43. Schade R, Andersohn F, Suissa S, et al. Dopamine Agonists and the Risk of  
459 Cardiac-Valve Regurgitation. *N Engl J Med* 2007; 356: 29–38.
- 460 44. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and Treatment of  
461 Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. *J Clin*  
462 *Endocrinol Metab* 2011; 96: 273–288.
- 463 45. Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, et al. Clinical guidelines  
464 for diagnosis and treatment of prolactinoma and hyperprolactinemia. *Endocrinol y*  
465 *Nutr (English Ed)* 2013; 60: 308–319.
- 466 46. Nakamura RK, Rishniw M, King MK, et al. Prevalence of echocardiographic  
467 evidence of cardiac disease in apparently healthy cats with murmurs. *J Feline Med*  
468 *Surg* 2011; 13: 266–271.
- 469 47. Paige CF, Abbott J a, Elvinger F, et al. Prevalence of cardiomyopathy in apparently

- 470 healthy cats. *J Am Vet Med Assoc* 2009; 234: 1398–1403.
- 471 48. Borgeat K, Niessen SJM, Wilkie L, et al. Time spent with cats is never wasted:  
472 Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring  
473 animal model of the human disease. *PLoS One* 2018; 13: e0194342.
- 474






476    Figures

477

478

479 Figure 1. Patient serum IGF1 at time points day 1, 30 and 90. There was no significant  
480 change of insulin-like growth factor 1 during the study ( $X^2(2) = 0.667$ ,  $P = 0.805$ ).

481




482

483

484

485 Figure 2. Patient serum fructosamine at time points day 1, 30 and 90. There was no  
486 significant change of fructosamine during the study,  $X^2(2) = 0.581$ ,  $P = 0.764$ .


487



488

489 Figure 3. Patient insulin dose at time points day 1, 30 and 90. There was a significant  
490 change of insulin dose prescribed during the study ( $X^2(2) = 8.667$ ,  $P = 0.008$ ), with cats  
491 receiving higher insulin doses on day 90 compared to day 1 (median day 1 was 0.98  
492 [range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg q12h,  $P =$   
493 0.026.)


494



495

496 Figure 4. Patient DIAQoL-pet scores on days 1 and 90. There was no significant change  
497 of DIAQoL-pet score ( $P = 0.715$ ).

498



499